A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Inactivating germ line BRCA 1‐associated protein‐1 (BAP1) mutations have recently been reported in families with uveal or cutaneous malignant melanoma (UMM, CMM), mesothelioma, and meningioma. Although apparently predisposing to a wide range of tumors, the exact tumor spectrum associated with germ line BAP1 mutations has yet to be established. Here, we report a novel germ line BAP1 splice mutation, c.1708 C>G (p.Leu570fs*40), in a multiple‐case D anish UMM family with a spectrum of other tumors. Whole‐exome sequencing identified an apparent missense mutation of BAP1 in UMM, CMM, as well as paraganglioma, breast cancer, and suspected mesothelioma cases in the family. Bioinformatic analysis and splicing assays demonstrated that this mutation creates a strong cryptic splice donor, resulting in aberrant splicing and a truncating frameshift of the BAP1 transcript. Somatic loss of the wild‐type allele was also confirmed in the UMM and paraganglioma tumors. Our findings further support BAP1 as a melanoma susceptibility gene and extend the potential predisposition spectrum to paraganglioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Cited by
Carbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R., & Gaudino, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3459 · Cited by 590
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Alternative tumour-specific antigens
Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 351
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
Germline BAP1 Mutations Predispose to Renal Cell Carcinomas
Popova, T., Hebert, L., Jacquemin, V., Gad, S., Caux-Moncoutier, V., Dubois-d’Enghien, C., Richaudeau, B., Renaudin, X., Sellers, J., Nicolas, A., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.012 · Cited by 279
Tumours associated with BAP1 mutations
Murali, R., Wiesner, T., & Scolyer, R. A. (2013) · Pathology · doi:10.1097/pat.0b013e32835d0efb · Cited by 270
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Baumann, F., Flores, E., Napolitano, A., Kanodia, S., Taioli, E., Pass, H., Yang, H., & Carbone, M. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu227 · Cited by 254
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144
“Other studies suggest that the clinical phenotype of the BAP1 syndrome may be expanded to other cancers such as lung adenocarcinoma, meningioma, breast carcinoma and paraganglioma (23-25).”
The genetics of melanoma: recent advances
Hill, V. K., Gartner, J. J., Samuels, Y., & Goldstein, A. M. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153429 · Cited by 86
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
Betti, M., Aspesi, A., Biasi, A., Casalone, E., Ferrante, D., Ogliara, P., Gironi, L. C., Giorgione, R., Farinelli, P., Grosso, F., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.011 · Cited by 78
Betti, M., Casalone, E., Ferrante, D., Romanelli, A., Grosso, F., Guarrera, S., Righi, L., Vatrano, S., Pelosi, G., Libener, R., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22218 · Cited by 71
“…al., 2014), but soon, more familial aggregations were observed, including epithelioid atypical Spitz tumors, adenocarcinoma, meningiomas, neuroendocrine tumors, breast cancer, prostate cancer, paraganglioma, and renal cell carcinomas (Wadt et al., 2012; Wiesner et al., 2012; Farley et al., 2013).”
BackgroundBetti, M., Aspesi, A., Ferrante, D., Sculco, M., Righi, L., Mirabelli, D., Napoli, F., Rondón‐Lagos, M., Casalone, E., Vignolo Lutati, F., et al. (2018) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22670 · Cited by 62
Metadata
- Authors
- Wadt, K., Choi, J., Chung, J., Kiilgaard, J., Heegaard, S., Drzewiecki, K. T., Trent, J. M., Hewitt, S. M., Hayward, N. K., Gerdes, A., & Brown, K. M.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2012-10
- Volume
- 25
- Issue
- 6
- Pages
- 815-818
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W2021420439
- Cited by
- 116
- References
- 1
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.